

(FILE 'HOME' ENTERED AT 14:14:53 ON 18 JUL 2005)

FILE 'STNGUIDE' ENTERED AT 14:15:04 ON 18 JUL 2005

FILE 'CAPLUS, USPATFULL' ENTERED AT 14:15:36 ON 18 JUL 2005

L1 762106 S EFFERVESCENT? OR ?CARBONATE
L2 72600 S PROGESTERON?
L3 49019 S VAGINA?
L4 4054 S (ADMINISTER? OR TREAT? OR CONTACT) (3A) L3
L5 197 S L4 AND L1 AND L2
L6 3 S L4 (P) L1 (P) L2

=>

L4 ANSWER 34 OF 35 USPATFULL on STN

ACCESSION NUMBER: 86:53749 USPATFULL

TITLE: Dry, water-foamable pharmaceutical compositions

INVENTOR(S): Chavkin, Leonard, Westfield, NJ, United States

PATENT ASSIGNEE(S): Health Products Development, Inc., Somerville, NJ,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4613497		19860923
APPLICATION INFO.:	US 1984-584788		19840229 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Schenkman, Leonard		
LEGAL REPRESENTATIVE:	Behr, Omri M.		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
LINE COUNT:	255		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A substantially anhydrous foamable composition capable of forming a substantially stable foam on contact with water is formed from a mixture of water soluble polysaccharide gum, an effervescent base and a biocompatible gelling salt. These compositions upon contact with water form extremely stable foams which are capable of acting as carriers for pharmaceutically active compositions.

DETD

EXAMPLE VIII

Contraceptive Gel for delivery by means of

Vaginal Applicator

Material	Mg. Per Dosage Unit
----------	---------------------

Nonoxynol-9	100.0
Sodium Alginate	800.0
Sodium Bicarbonate	500.0
Citric Acid	500.0
Polyethylene Glycol	1500
	1000.0
Calcium Gluconate	200.0
TOTAL	3100.0 mg.

L8 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1987:561499 CAPLUS

DOCUMENT NUMBER: 107:161499

TITLE: Bioavailability of progesterone with different modes of administration

AUTHOR(S): Chakmakjian, Zaven H.; Zachariah, Nannepaga Y.

CORPORATE SOURCE: Med. Cent., Baylor Univ., Dallas, TX, USA

SOURCE: Journal of Reproductive Medicine (1987), 3(6), 443-8
CODEN: JRPMP; ISSN: 0024-7758

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The bioavailability of micronized progesterone (I) was studied by measuring sequential serum I concns. after a single bolus of 50-200 mg I given sublingually, orally (capsule and tablet), vaginally and rectally (suppositories) during the follicular phase in a group of normally menstruating women. When compared to other modes of I administration, the area under the curve during the first 8 h was twice as high with the rectal route. With 50 and 100 mg I given sublingually and 100 and 200 mg ingested as tablets, peak levels and area under the curve were twice as high with the higher dosage. The response was more sustained with the higher dosage. All subjects exhibited a significant increase in serum I levels over baseline that persisted for at least 8 h. The I levels were still increased over baseline at 24 h in all subjects after the administration of 100-mg vaginal and rectal suppositories and 200-mg tablets. These findings are in general agreement with previous reports showing that luteal phase serum I concns. can be reached easily with nonparenteral modes of administering micronized I and that oral I administration could become an attractive alternative to the currently used oral mode of administering synthetic progestins.

L4 ANSWER 32 OF 35 USPATFULL on STN
 ACCESSION NUMBER: 89:62848 USPATFULL
 TITLE: Stable, effervescent vaginal suppositories
 INVENTOR(S): Kurobe, Toshio, Saitama, Japan
 Kasai, Masayoshi, Saitama, Japan
 Kayano, Masanori, Saitama, Japan
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4853211		19890801
APPLICATION INFO.:	US 1987-117398		19871028 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1986-827216, filed on 5 Feb 1986, now abandoned which is a continuation of Ser. No. US 1984-628977, filed on 12 Jul 1984, now abandoned which is a continuation of Ser. No. US 1983-471453, filed on 2 Mar 1983, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1982-34034	19820305
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Schenkman, Leonard	
LEGAL REPRESENTATIVE:	Wenderoth, Lind & Ponack	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	296	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An effervescent vaginal suppository composition containing a stabilizer appropriately selected from the group consisting of anhydrous sodium sulfate, anhydrous silica gel, dried magnesium silicate, dried aluminum silicate, dried calcium carboxymethylcellulose, dried microcrystalline cellulose, dried starch and dried calcium phosphate or mixtures thereof, preferably in an amount of 0.1-20% based on the weight of said effervescent vaginal suppository composition. Shaped effervescent vaginal suppositories are produced therefrom.

CLM What is claimed is:
 . the weight of the suppository composition, of anhydrous sodium sulfate as stabilizer, (B) an amount sufficient to achieve effervescence upon **contact** with **vaginal** body fluid of an effervescing agent which is a combination of: (1) at least one acidic substance selected from the . . . soluble acid alkali metal salts thereof, and (2) at least one basic substance selected from the group consisting of sodium **bicarbonate** and potassium **bicarbonate**, the ratio of (1):(2) being sufficient to achieve effervescence of the composition upon **contact** with **vaginal** body fluid, (C) a base for vaginal suppository, and (D) an effective amount of a member selected from the group. . .